Literature DB >> 18571084

Macular and visual outcomes after cataract extraction for highly myopic foveoschisis.

Chi-Chun Lai1, Ling Yeung, Yen-Po Chen, Nan-Kai Wang, Wei-Chi Wu, Kuan-Jen Chen, Lan-Hsin Chuang, Tun-Lu Chen.   

Abstract

PURPOSE: To evaluate the macular and visual changes after cataract extraction in patients with myopic foveoschisis.
SETTING: Chang Gung Memorial Hospital, Taoyuan, Taiwan.
METHODS: This retrospective study reviewed the charts of 20 eyes (14 patients) with myopic foveoschisis that had phacoemulsification. All eyes except 1 had intraocular lens implantation. The preoperative and postoperative best corrected visual acuities (BCVAs) were documented. The central foveal thickness and morphology were examined by optical coherence tomography.
RESULTS: The mean postoperative follow-up was 15.6 months+/-9.6 (SD). The mean preoperative BCVA of 1.35+/-0.65 logMAR improved to 0.47+/-0.38 logMAR 1 month after surgery (P<.001) and to 0.40+/-0.40 logMAR at 3 months (P<.001 versus preoperatively; P=.01 versus 1 month). The BCVA stabilized to a mean of 0.40+/-0.41 logMAR at 6 months and was 0.37+/-0.39 logMAR at the last visit. The mean central foveal thickness was 297+/-107 microm preoperatively, 321+/-108 microm 1 month postoperatively (P<.001), and 347+/-120 microm at 3 months (P=.001). The central foveal thickness stabilized at 6 months (mean 357+/-115 microm).
CONCLUSIONS: Visual acuity improved and central foveal thickness increased after cataract extraction in patients with myopic foveoschisis. There were no emergent macular changes.

Entities:  

Mesh:

Year:  2008        PMID: 18571084     DOI: 10.1016/j.jcrs.2008.02.033

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  1 in total

1.  Long-term outcomes of patients with myopic traction maculopathy after phacoemulsification for incident cataract.

Authors:  Lei Cai; Zhongcui Sun; Diwen Guo; Qi Fan; Xiangjia Zhu; Jin Yang; Yi Lu
Journal:  Eye (Lond)       Date:  2019-04-05       Impact factor: 3.775

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.